The patent application WO2003077914A1, titled "MEK INHIBITORS," details compounds that inhibit MEK, a key enzyme in the MAPK signaling pathway. This pathway is frequently dysregulated in various cancers [1]. Binimetinib is one such MEK inhibitor developed from this research [2].
What is Binimetinib and How Does It Work?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 [2]. These enzymes are crucial components of the RAS-RAF-MEK-ERK pathway, which plays a significant role in cell growth, proliferation, and survival. By inhibiting MEK, binimetinib disrupts this signaling cascade, leading to reduced tumor cell growth and increased apoptosis [1][2]. It is indicated for the treatment of certain types of melanoma with specific genetic mutations [3].
When Does the Patent for Binimetinib Expire?
Determining the exact patent expiry date for a drug like binimetinib can be complex due to multiple patents covering different aspects, such as the compound itself, its synthesis, formulations, and methods of use. These patents can have varying expiry dates. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals [4]. Publicly available information suggests that primary patents for binimetinib may expire around the mid-2020s, but this can be influenced by patent extensions and additional filings [4].
What Other MEK Inhibitors Are Available?
Other MEK inhibitors have been developed and approved for use. Trametinib is another MEK inhibitor that, like binimetinib, targets the MEK1 and MEK2 enzymes [5]. Both drugs are often used in combination therapies for specific cancer types [3][5].
What Are the Side Effects of Binimetinib?
Common side effects associated with binimetinib treatment can include fatigue, rash, nausea, diarrhea, and headache [3]. More serious side effects may also occur, and patients should discuss potential risks with their healthcare provider [3].
Who Developed Binimetinib?
Binimetinib was developed by Array BioPharma, which was later acquired by Pfizer [6].
How is Binimetinib Used in Cancer Treatment?
Binimetinib is primarily used in combination with other targeted therapies, such as BRAF inhibitors, for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [3]. It may also be investigated for other cancers driven by the MAPK pathway [1][2].
Can Generic Versions of Binimetinib Be Made Before Patent Expiry?
Generally, generic versions of a drug cannot be manufactured and marketed until the relevant patents expire or are successfully challenged [4]. The development and approval process for biosimilars or generics involves demonstrating equivalence to the reference product and navigating the patent landscape [4].
Sources:
[1] https://patents.google.com/patent/WO2003077914A1/en
[2] https://www.drugbank.ca/drugs/binimetinib
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-braftovi-encorafenib-and-mektovi-binimetinib-unresectable-or-metastatic-melanoma
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tafinlar-dabrafenib-and-mekinist-trametinib-new-indications
[6] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-array-biopharma